Wave Life Sciences Ltd.
NASDAQ:WVEBiotechnology
+$0.10 today
- Market cap
- $546.32M
- Beta
- -1.33
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$0.92
Volume 2.21M
Average 4.86M
WVE Account Payables
Amounts the company owes suppliers for goods and services received.
Wave Life Sciences Ltd.NASDAQ: WVE
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 32.8% from a year ago
Account payables stood at $19.06M at the end of Q1 FY2026, up 32.8% from a year earlier and up 21.4% from the prior quarter. Over 3 fiscal years it compounded at -2.5% a year.
Context
- Account payables amounted to 3.3% of total assets at the end of Q1 FY2026, down 1.7 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +32.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 15.7M USD
- Year-over-year change
- -3.5%
- 4-year CAGR
- +21.2%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.7M | -3.5% |
| FY2024 | 2024-12-31 | 16.26M | +26.7% |
| FY2023 | 2023-12-31 | 12.84M | -24.1% |
| FY2022 | 2022-12-31 | 16.92M | +132.3% |
| FY2021 | 2021-12-31 | 7.28M | — |
Account Payables vs competitors
How WVE compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +32.8% is the 6th highest of 11, against a peer median of +26.1%.
- Account payables amounts to 3.3% of total assets for WVE, versus a peer median of 1.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $108.02M USD | +5.5% | +5.7% | 1.9% | |
| Mar 2026 | $70.38M USD | -54.9% | +43.1% | 2.2% | |
| Sep 2026 | $30.15M USD | +70.6% | -5.6% | 1.7% | |
| Sep 2026 | $27.11M USD | +89.3% | +16.2% | 0.9% | |
| Mar 2026 | $19.06M USD | +32.8% | -2.5% | 3.3% | |
| Mar 2026 | $18.8M USD | +52.1% | +57.8% | 2.5% | |
| Mar 2026 | $10.37M USD | -44.9% | +11.4% | 9.0% | |
| Mar 2026 | $6.84M USD | +212.9% | +86.1% | 1.5% | |
| Mar 2026 | $4.09M USD | -33.8% | -17.2% | 1.7% | |
| Mar 2026 | $635K USD | +46.7% | -21.9% | 0.3% | |
| Mar 2026 | €189.2K EUR | -57.7% | -8.7% | 0.2% | |
| Peer median (excluding WVE) | — | +26.1% | +8.6% | 1.7% | |
Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 150.56M | 88.5M | 200.35M | 302.08M | 602.07M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 21.09M | 1.42M | 1.28M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 5.42M | 2.11M | 4.02M | 7.35M | 3.08M |
| Total Current Assets | 162.56M | 98.54M | 235.37M | 320.39M | 614.81M |
| Property, Plant & Equipment (Net) | 40.64M | 44.13M | 35.72M | 28M | 19.86M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 3.81M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.8M | 3.72M | 3.86M | 3.82M | 16K |
| Total Non-current Assets | 44.44M | 47.85M | 39.58M | 31.81M | 23.69M |
| Total Assets | 207.01M | 146.39M | 274.95M | 352.21M | 638.5M |
| Account Payables | 7.28M | 16.92M | 12.84M | 16.26M | 15.7M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 37.1M | 31.56M | 150.06M | 65.97M | 44.44M |
| Other Current Liabilities | 10.18M | 12.29M | 14.07M | 15.36M | 18.08M |
| Total Current Liabilities | 64.2M | 71.52M | 186.44M | 110.95M | 95.07M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 77.48M | 79.77M | 15.6M | 6.1M | 7.8M |
| Other Non-current Liabilities | 7.87M | 8.06M | 7.87M | 7.87M | 0 |
| Total Non-current Liabilities | 110.31M | 119.96M | 48.88M | 31.74M | 17.2M |
| Total Liabilities | 174.51M | 191.48M | 235.32M | 142.69M | 112.27M |
| Common Stock | 749.85M | 802.83M | 935.37M | 1.18B | 1.62B |
| Retained Earnings | (805.51M) | (967.34M) | (1.02B) | (1.12B) | (1.33B) |
| Accumulated OCI | 181K | (29K) | (124K) | (262K) | (250K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 32.5M | (45.09M) | 39.63M | 209.52M | 526.23M |
| Total Debt | 29.92M | 37.61M | 32.12M | 25.4M | 17.77M |
| Net Debt | (120.65M) | (50.88M) | (168.23M) | (276.67M) | (584.3M) |
Wave Life Sciences Ltd.
NASDAQ:WVE
Intrinsic Alpha fair value
Locked
Current Price
$2.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.